Related Articles
Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer
Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2‑negative breast cancer: A meta‑analysis of randomized controlled trials
Comparing the cost-effectiveness of FOLFIRINOX, nab-paclitaxel plus gemcitabine, gemcitabine and S-1 for the treatment of metastatic pancreatic cancer
The efficacy and safety of bevacizumab in addition to platinum‑based chemotherapy for the first‑line treatment of patients with advanced nonsquamous non‑small‑cell lung cancer: Final results of AVALANCHE, an observational cohort study
Potential plasticity of T regulatory cells in pancreatic carcinoma in relation to disease progression and outcome